Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Abstract Background Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy...

Full description

Bibliographic Details

Published in:	JNCI : Journal of the National Cancer Institute Vol. 113; no. 8; pp. 1005 - 1016
Main Authors:	Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Nguyen-Duc, Anh, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, Schmid, Peter
Format:	Journal Article
Language:	English
Published:	United States Oxford University Press 02.08.2021
Subjects:	Albumins Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - metabolism Biomarkers Humans Lymphocytes, Tumor-Infiltrating - pathology Paclitaxel Triple Negative Breast Neoplasms - pathology Tumor Microenvironment
ISSN:	0027-8874, 1460-2105, 1460-2105
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!